Clinigence Holdings (NUTX) Price & Analysis

Compare

389 Followers

NUTX Stock Chart & Stats

$184.11

-$1.17(-3.51%)

At close: Jan 08 4:00 PM EST

$184.11

-$1.17(-3.51%)

Day’s Range― - ―

52-Week Range$45.88 - $193.07

Previous CloseN/A

Volume3.28K

Average Volume (3M)207.03K

Market Cap

$661.85M

Enterprise Value$731.36M

Total Cash (Recent Filing)$185.57M

Total Debt (Recent Filing)$351.39M

Price to Earnings (P/E)15.6

Beta2.37

Next Earnings

May 19, 2026

EPS Estimate

3.99

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.69

Shares Outstanding6,968,350

10 Day Avg. Volume203,944

30 Day Avg. Volume207,030

Financial Highlights & Ratios

PEG Ratio1.77

Price to Book (P/B)3.35

Price to Sales (P/S)1.26

P/FCF Ratio4.49

Enterprise Value/Market Cap1.11

Enterprise Value/Revenue0.84

Enterprise Value/Gross Profit1.65

Enterprise Value/Ebitda2.62

Forecast

1Y Price Target

$225.00

Price Target Upside22.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)19.78

Revenue Forecast (FY)$989.61M

Bulls Say, Bears Say

Bulls Say

Expansion PlansNutex reopened a micro-hospital in Red River, Texas, and plans to open 5-6 additional de novo micro-hospitals by the end of 2026.

Financial StabilityNutex has sufficient capital to maintain current operations and advance expansion plans, with cash of $96.4M and debt of $35.5M as of June 30, 2025.

Revenue GrowthNutex Health Inc. reported revenue and GAAP EPS significantly above consensus and estimates, with revenue up 240%.

Bears Say

Accounting IssuesNutex filed an NT 10-Q notification of inability to timely file its 10-Q due to the incorrect accounting classification of certain non-cash obligations, leading to the need for restatements.

Legal ChallengesPotential headwinds to NUTX's stock price include accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD.

Clinigence Holdings News

Morning Movers: Nutex Health sinks after fourth quarter results

Futures are lower this morning with investors continuing to price the macro and geopolitical shock stemming from the...

18d ago

AQN

GAP

Nutex Health reports Q4 revenue $151.7M vs. $257.6M last year

Net income attributable to Nutex Health (NUTX) for the three months ended December 31, 2025 was $11.8M as...

18d ago

NUTX

Closing Bell Movers: Marvell up 15% after earnings beat

Hope for a quicker resolution to the Middle East conflict after yesterday’s rumored contact between Iranian authorities and...

18d ago

GAP

IOT

Nutex Health reports Q4 EPS $10.48 vs. last year

Reports Q4 revenue $151.7M, consensus $258.82M. The company attributes the $105.9M revenue decrease primarily to two items: a...

18d ago

NUTX

Nutex Health reports 2025 EPS $10.48 vs. $9.69 in 2024

18:42 EST Nutex Health (NUTX) reports 2025 EPS $10.48 vs. $9.69 in 2024 Published first on TheFly –...

18d ago

NUTX

Nutex Health authorizes $25M share repurchase program

Nutex Health (NUTX) has authorized a second stock repurchase program of up to $25.0M of the company’s common...

18d ago

NUTX

Clinigence Holdings Earnings Call Highlights Rapid Growth

Clinigence Holdings Inc (($NUTX)) has held its Q4 earnings call. Read on for the main highlights of the...

14d ago

NUTX

Nutex Health extends stock repurchase program

Nutex Health (NUTX) announced that its board of directors has approved an extension of the previously authorized stock...

4M ago

NUTX

Nutex Health extends stock repurchase program

Nutex Health (NUTX) announced that its board of directors has approved an extension of the previously authorized stock...

4M ago

NUTX

Nutex Health says ‘Capybara Research as an entity seems not to exist’

“Nutex Health (NUTX) is aware of a short seller report issued on November 25, 2025 by Capybara Research....

4M ago

NUTX

Capybara Research believes Nutex Health engaged in fraudulent business practices

Capybara Research said in a recently published report that it sees “problems at Nutex.” “Over a dozen Nutex...

4M ago

NUTX

Clinigence Holdings Files Auditors’ Consent for Nutex

An announcement from Clinigence Holdings ( ($NUTX) ) is now available. Clinigence Holdings has filed an auditors’ consent...

4M ago

NUTX

Nutex Health Inc. Reports Strong Revenue Growth

Clinigence Holdings Inc ( ($NUTX) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

NUTX

Nutex Health Delays Quarterly Report Filing

Clinigence Holdings ( ($NUTX) ) has released a notification of late filing. Nutex Health Inc. has announced a...

4M ago

NUTX

NUTX FAQ

What was Clinigence Holdings Inc’s price range in the past 12 months?

Clinigence Holdings Inc lowest stock price was $45.88 and its highest was $193.07 in the past 12 months.

What is Clinigence Holdings Inc’s market cap?

Clinigence Holdings Inc’s market cap is $661.85M.

When is Clinigence Holdings Inc’s upcoming earnings report date?

Clinigence Holdings Inc’s upcoming earnings report date is May 19, 2026 which is in 56 days.

How were Clinigence Holdings Inc’s earnings last quarter?

Clinigence Holdings Inc released its earnings results on Mar 05, 2026. The company reported $1.693 earnings per share for the quarter, missing the consensus estimate of $5.557 by -$3.864.

Is Clinigence Holdings Inc overvalued?

According to Wall Street analysts Clinigence Holdings Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinigence Holdings Inc pay dividends?

Clinigence Holdings Inc does not currently pay dividends.

What is Clinigence Holdings Inc’s EPS estimate?

Clinigence Holdings Inc’s EPS estimate is 3.99.

How many shares outstanding does Clinigence Holdings Inc have?

Clinigence Holdings Inc has 6,968,350 shares outstanding.

What happened to Clinigence Holdings Inc’s price movement after its last earnings report?

Clinigence Holdings Inc reported an EPS of $1.693 in its last earnings report, missing expectations of $5.557. Following the earnings report the stock price went down -14.297%.

Which hedge fund is a major shareholder of Clinigence Holdings Inc?

Currently, no hedge funds are holding shares in NUTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinigence Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

23.80%

Trailing 12-Months

Asset Growth

37.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clinigence Holdings Inc

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

Clinigence Holdings (NUTX) Earnings & Revenues

Historic Earnings Reports

NUTX Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presents a predominantly positive long‑term operational and financial story—very strong full‑year revenue growth (+82.4%), major margin and cash‑flow improvements, profitable and expanding IPAs, high patient satisfaction, and disciplined capital allocation. The principal negatives were a material, timing‑driven Q4 revenue/earnings hit from a CMS‑driven IDR true‑up and a large one‑time stock‑based compensation charge; these items created quarter volatility but appear to be nonrecurring or better understood by management. Given the substantial year‑over‑year improvements in revenue, adjusted EBITDA, cash flow and margins that outweigh the one‑time/quarterly headwinds and controllable operational initiatives underway, the overall sentiment is positive.View all NUTX earnings summaries

NUTX Stock 12 Month Forecast

Average Price Target

$225.00

▲(22.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","301":"$301","109.75":"$109.8","173.5":"$173.5","237.25":"$237.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$225.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,109.75,173.5,237.25,301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.6,131.63076923076923,145.66153846153844,159.69230769230768,173.72307692307692,187.75384615384615,201.7846153846154,215.8153846153846,229.84615384615384,243.87692307692308,257.9076923076923,271.9384615384615,285.96923076923076,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.6,125.86153846153846,134.12307692307692,142.3846153846154,150.64615384615385,158.90769230769232,167.16923076923075,175.43076923076922,183.69230769230768,191.95384615384614,200.2153846153846,208.47692307692307,216.73846153846154,{"y":225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.6,120.09230769230768,122.58461538461538,125.07692307692307,127.56923076923077,130.06153846153845,132.55384615384617,135.04615384615386,137.53846153846155,140.03076923076924,142.52307692307693,145.01538461538462,147.5076923076923,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.58,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >